Medical Condition News

RSS

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Stricter glucose control may affect quality of life in people living with diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in people living with diabetes (type 1 or 2) using data from continuous glucose monitoring (CGM) devices paired with daily quality-of-life ratings, days with more widely fluctuating glucose readings (while still within safe limits) are followed by days with a better quality life compared to days with more stricter control– suggesting the burden of that stricter control could be preventing those individuals with stricter control from enjoying various activities.

11 Sep 2026

Distinct EFEMP1 variants cause different forms of vision loss

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision.

11 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Video game offers new insights into autistic perception

People with autism often come at life from a different angle-seeing details others miss, focusing on patterns rather than faces, experiencing heightened or dimmed physical sensations.

11 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

Obesity suppresses natural protection against breast cancer growth

A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason why obesity is a risk factor for breast cancer.

11 Sep 2026

Lupus-linked genetic variants may boost antiviral immunity

Why do genetic variants that increase the risk of autoimmune disease remain so common in the population?

11 Sep 2026

Giant-nucleus cells form the foundation of early-stage cancer

Iron is an essential micronutrient, but excess iron can damage cells and increase cancer risk. While many cells die from iron-induced oxidative stress, a subset survives and may become cancerous.

11 Sep 2026

Finnish study finds working from home increases sedentary behavior

According to a Finnish study, people sleep slightly longer when they work from home. However, they also sit more and are less physically active than on days when they work in the office.

11 Sep 2026

Early treatment significantly reduces joint damage in rheumatoid arthritis

Early and consistently managed treatment can have a decisive impact on the course of rheumatoid arthritis and prevent permanent joint damage.

11 Sep 2026

Neighborhood environments impact long-term health of 9/11 responders

Twenty-five years after the September 11 terrorist attacks, researchers at the Icahn School of Medicine at Mount Sinai have found that environmental conditions where World Trade Center responders live may influence their long-term physical and mental health.

11 Sep 2026